Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycoursodeoxycholic acid (GUDCA) is a glycine-conjugated form of ursodeoxycholic acid. It is an endogenous bile acid metabolite with regulatory effects on bile acid metabolism and gut microbiota. Preclinical studies show that GUDCA supplementation improves metabolic profiles by decreasing blood glucose, ameliorating insulin resistance and hepatic steatosis, and providing hepatoprotective and neuroprotective effects. Mechanistically, GUDCA has been shown to inhibit the intestinal FXR axis, modulate ER stress, suppress apoptosis, and alter the bile acid pool composition, suggesting a role in the management of metabolic disorders such as diabetes and non-alcoholic fatty liver disease[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glycoursodeoxycholic acid.